desidustat

a prolyl hydroxylase domain protein inhibitor

Also Known As:

2-(1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid; Glycine, N-((1-(cyclopropylmethoxy)-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl)-; N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine; ZYAN1 compound

Networked: 11 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        desidustat: 11

Experts

1.	Jain, Mukul R: 2 articles (01/2022 - 01/2021)
2.	Joharapurkar, Amit A: 2 articles (01/2022 - 01/2021)
3.	Kanani, Pooja: 2 articles (01/2022 - 01/2022)
4.	Kansagra, Kevinkumar: 2 articles (01/2022 - 01/2022)
5.	Kshirsagar, Samadhan G: 2 articles (01/2022 - 01/2021)
6.	Patel, Maulik S: 2 articles (01/2022 - 01/2021)
7.	Patel, Vishal J: 2 articles (01/2022 - 01/2021)
8.	Rajanna, Sunil: 2 articles (01/2022 - 01/2022)
9.	Ruhela, Vivek: 2 articles (01/2022 - 01/2022)
10.	Savsani, Hardikkumar H: 2 articles (01/2022 - 01/2021)

Related Diseases

1.	Anemia 01/01/2019 - "This trial evaluated the safety, tolerability, and efficacy of Desidustat in adult CKD patients with anemia, who were not on dialysis. " 01/01/2022 - "In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated. " 01/01/2022 - "Desidustat is non-inferior to darbepoetin in the treatment of anemia due to non-dialysis dependent CKD and it is well-tolerated." 01/01/2022 - "Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)." 01/01/2022 - "Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)."
2.	Inflammation (Inflammations) 01/01/2021 - "Desidustat treatment reduced the renal fibrosis and inflammation along with a reduction in anemia in preclinical models of kidney injury, which may translate to protective effects in CKD patients." 01/15/2019 - "In the current work using rodent models of inflammation, an orally available small molecule prolyl hydroxylase inhibitor desidustat was assessed as an effective treatment of anemia of inflammation. " 01/01/2022 - "Thus, novel prolyl hydroxylase inhibitor desidustat can treat EPO resistance via improved iron utilization and decreased inflammation." 01/15/2019 - "In BALB/c mice, a single dose treatment of desidustat attenuated the effect of lipopolysaccharide (LPS) - or turpentine oil-induced inflammation and increased serum erythropoietin (EPO), iron, and reticulocyte count, and decreased serum hepcidin levels. "
3.	Fibrosis (Cirrhosis) 01/01/2021 - "Desidustat treatment also reduced renal fibrosis as observed by histological analysis and hydroxyproline content. " 01/01/2021 - "Desidustat treatment reduced the renal fibrosis and inflammation along with a reduction in anemia in preclinical models of kidney injury, which may translate to protective effects in CKD patients."
4.	Chronic Renal Insufficiency 01/01/2022 - "Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)." 01/01/2022 - "Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)." 01/01/2019 - "Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study." 01/01/2023 - "Desidustat (DES) belongs to a new category of drugs, i.e., Hypoxia-Inducible Factor (HIF) propyl hydroxylase inhibitor, and is used for the treatment of anemia in chronic kidney disease. " 01/01/2022 - "Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency. "
5.	Hypoxia (Hypoxemia) 01/01/2019 - "Desidustat (ZYAN1) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis. " 01/01/2022 - "This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on EPO-refractory renal anemia. " 01/01/2023 - "Desidustat (DES) belongs to a new category of drugs, i.e., Hypoxia-Inducible Factor (HIF) propyl hydroxylase inhibitor, and is used for the treatment of anemia in chronic kidney disease. " 01/01/2022 - "Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency. " 07/01/2022 - "Desidustat (Oxemia™) is an orally bioavailable, small molecule, hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor developed by Zydus Cadila for the treatment of anaemia associated with chronic kidney disease (CKD), COVID-2019 infections and chemotherapy induced anaemia. "

Related Drugs and Biologics

1.	Prolyl-Hydroxylase Inhibitors
2.	Hemoglobins (Hemoglobin)
3.	Hepcidins
4.	Iron
5.	Urea (Carbamide)
6.	Creatinine
7.	Adenine
8.	vadadustat
9.	GSK1278863
10.	Epoetin Alfa (Epogen)

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Drug Therapy (Chemotherapy)